Elanco Animal Health Incorporated (ELAN) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ELAN Revenue Growth
Revenue Breakdown (FY 2025)
ELAN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ELAN Revenue Analysis (2016–2025)
As of May 7, 2026, Elanco Animal Health Incorporated (ELAN) generated trailing twelve-month (TTM) revenue of $4.89 billion, reflecting strong growth of +14.9% year-over-year. The most recent quarter (Q1 2026) recorded $1.37 billion in revenue, up 19.8% sequentially.
Looking at the longer-term picture, ELAN's 5-year compound annual growth rate (CAGR) stands at +7.6%, indicating steady revenue expansion. The company achieved its highest annual revenue of $4.76 billion in 2021.
Revenue diversification analysis shows ELAN's business is primarily driven by Farm Animal (33%), Pet Health (32%), and Cattle (16%).
When compared to Healthcare sector peers including ZTS (+2.3% YoY), PCRX (+4.6% YoY), and PAHC (+32.4% YoY), ELAN has underperformed the peer group in terms of revenue growth. Compare ELAN vs ZTS →
ELAN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ELANCurrent | $4.9B | +14.9% | +7.6% | 5.3% | |
 ZTS | $9.5B | +2.3% | +7.2% | 38.0% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% | |
 NEOG | $895M | -3.7% | +16.4% | 1.1% | |
 PETS | $227M | -24.8% | -4.4% | -0.7% |
ELAN Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.71B | +6.2% | $2.05B | 43.5% | $252.0M | 5.3% |
| 2024 | $4.44B | +0.5% | $1.91B | 43.0% | $251.0M | 5.7% |
| 2023 | $4.42B | +0.1% | $1.94B | 43.9% | $326.0M | 7.4% |
| 2022 | $4.41B | -7.4% | $1.97B | 44.7% | $384.0M | 8.7% |
| 2021 | $4.76B | +45.5% | $2.08B | 43.6% | $304.0M | 6.4% |
| 2020 | $3.27B | +6.6% | $1.25B | 38.1% | $-76,800,000 | -2.3% |
| 2019 | $3.07B | +0.1% | $1.40B | 45.6% | $370.0M | 12.0% |
| 2018 | $3.07B | +6.2% | $1.30B | 42.2% | $313.8M | 10.2% |
| 2017 | $2.89B | -0.8% | $1.17B | 40.6% | $142.4M | 4.9% |
| 2016 | $2.91B | - | $1.33B | 45.8% | $283.2M | 9.7% |
Full ELAN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ELAN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ELAN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ELAN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonELAN — Frequently Asked Questions
Quick answers to the most common questions about buying ELAN stock.
Is ELAN's revenue growth accelerating or slowing?
ELAN maintains +14.9% revenue growth, in line with its 5-year CAGR of +7.6%. TTM revenue stands at $4.9B. Growth rate remains consistent with historical average.
What is ELAN's long-term revenue growth rate?
Elanco Animal Health Incorporated's 5-year revenue CAGR of +7.6% reflects the sustained expansion pattern. Current YoY growth of +14.9% is near this long-term average.
How is ELAN's revenue distributed by segment?
ELAN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.